🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against increasingly resistant strains of the bacteria, according to researchers.

An International Challenge

Cases of gonorrhoea are on the rise globally, with estimates suggesting over 82 million new cases each year. Notably increased rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the context of rising global incidence, the spread of superbugs and the highly restricted therapeutic options at this time.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This approval represents a significant shift in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Clinical Trial Results and Worldwide Availability

As per findings released by a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which involves two antibiotics. The trial enrolled nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have voiced hope. The availability of a single-dose, oral treatment like this is described as a "game-changer" for gonorrhoea control. This is considered crucial to alleviate the strain of the disease for people and to prevent the spread of untreatable gonorrhoea globally.